TrialThe Journal of urology2025

Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION).

Sandip M Prasad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.